Cerevance closes $20M Series C as Phase 3 Parkinson's trial fully enrolled
What's the deal? Cerevance, a clinical-stage biopharma company based in Boston, has closed an oversubscribed $20 million Series C and completed enrollment in its pivotal Phase 3 trial for a Parkinson's disease therapy. The ARISE trial enrolled 341 patients across the US, Europe, the UK, and Australia to test solengepras, a potential first-in-class, non-dopaminergic treatment for daily OFF periods — hours when symptoms return despite medication.
The round was backed entirely by existing investors, including Double Point VenturesDealroom has a profile for this one. Try Dealroom →, Gates FrontierDealroom has a profile for this one. Try Dealroom →, Google Ventures, Lightstone VenturesDealroom has a profile for this one. Try Dealroom →, MQB Partners, SV Health Investors' Dementia Discovery Fund, and UPMC. Proceeds will extend Cerevance's cash runway into mid-2027.
Topline data from the trial is expected at the end of Q3 2026.
Why now? Solengepras targets the GPR6 receptor rather than the dopamine system, offering a fundamentally different mechanism from existing Parkinson's treatments. More than 10 million people worldwide live with Parkinson's disease, and motor fluctuations remain one of the most persistent challenges in managing it. Current dopaminergic therapies leave a substantial gap in care and come with well-known side effects.
Cerevance's Phase 2 trial showed solengepras reduced OFF time with a favourable tolerability profile, giving investors enough confidence to oversubscribe the Series C.
What could go wrong? Phase 3 trials are notoriously high-stakes in biopharma. Promising Phase 2 results frequently fail to replicate in larger, pivotal studies. If ARISE misses its endpoints, Cerevance would face a difficult fundraising environment with a runway that only extends to mid-2027.
The company also operates in a competitive space. Any rival breakthroughs in Parkinson's treatment could diminish solengepras's commercial potential even if the trial succeeds.
The signal: Cerevance's investor roster — spanning Gates Frontier, Google Ventures, and SV Health Investors' Dementia Discovery Fund — reflects a deliberate convergence of tech-adjacent capital and specialist life-science funds around neurodegenerative disease, a category historically starved of venture conviction. That every dollar in this round came from existing backers, with no new lead brought in, suggests the syndicate is doubling down on Phase 2 data rather than seeking external validation in a biotech funding climate that remains punishing for pre-revenue companies.
Read more: Business Insider
